TECHNETIUM TC 99M TSC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNETIUM TC 99M TSC (TECHNETIUM TC 99M TSC).
Technetium Tc 99m TSC is a radiopharmaceutical that binds to activated leukocytes, primarily neutrophils, via interaction with integrin receptors (e.g., CD11b/CD18), allowing imaging of inflammation and infection.
| Metabolism | No significant metabolism; technetium-99m decays by isomeric transition to technetium-99 with a half-life of 6.02 hours, emitting gamma rays. |
| Excretion | Renal: ~50% excreted unchanged in urine within 24 hours; remainder eliminated via hepatobiliary system into feces. |
| Half-life | Terminal half-life approximately 6 hours; allows for same-day imaging but requires prompt scanning due to radionuclide decay. |
| Protein binding | Minimal binding to plasma proteins; predominantly free in circulation. |
| Volume of Distribution | Approximately 0.2 L/kg; distributes primarily in extracellular fluid. |
| Bioavailability | 100% bioavailability by intravenous route; no oral administration. |
| Onset of Action | Intravenous: distribution phase begins immediately; blood pool clearance within minutes. |
| Duration of Action | Effective imaging window 1–6 hours post-injection; radionuclide decay limits utility beyond 24 hours. |
1-10 mCi (37-370 MBq) intravenously as a single dose for imaging studies; dose depends on indication and imaging protocol.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment required for GFR; Tc-99m TSC is cleared by the reticuloendothelial system, not primarily renal. |
| Liver impairment | No specific dose adjustment recommended; however, impaired hepatic function may alter biodistribution; use caution in severe hepatic impairment. |
| Pediatric use | Weight-based dosing: 0.05-0.15 mCi/kg (1.85-5.55 MBq/kg) intravenously, minimum dose 1 mCi (37 MBq); adjust per institutional protocol. |
| Geriatric use | No specific dose adjustment; standard adult dose used; consider reduced organ function and hydration status with advanced age. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNETIUM TC 99M TSC (TECHNETIUM TC 99M TSC).
| Breastfeeding | Technetium Tc 99m enters breast milk. American College of Radiology recommends breastfeeding interruption for 24 hours after administration; expressed milk should be discarded. M/P ratio not established. Consider using alternative imaging if possible. |
| Teratogenic Risk | Technetium Tc 99m is a radioactive isotope used in imaging. Fetal radiation exposure from diagnostic doses is typically <50 mGy, considered low risk. No known teratogenic effects at diagnostic levels; however, during organogenesis (weeks 2-8), theoretical risk of stochastic effects exists. Second and third trimester exposure carries lower risk of malformation but potential for childhood cancer. Radiation dose should be minimized per ALARA principle. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to technetium or any component of the formulation.","Pregnancy: Avoid unless benefit justifies risk; alternative imaging should be considered.","Lactation: Interrupt breastfeeding for at least 24 hours after administration."]
| Precautions | ["Radiation exposure: Risk of cancer and genetic defects from ionizing radiation; use lowest necessary dose.","Hypersensitivity: Allergic reactions including anaphylaxis have been reported.","Impurities: Sodium pertechnetate or other impurities may cause altered biodistribution; verify radiochemical purity prior to use.","Interference: Recent use of other radiopharmaceuticals or contrast agents may affect imaging results."] |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required. Confirm pregnancy status prior to administration. Minimize radiation exposure using lowest effective dose and shortest half-life tracer. |
| Fertility Effects | No known effects on fertility from diagnostic doses. Higher doses (>100 mGy) may affect ovarian function, but such doses are not used in standard imaging. |